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There is uncertainty about the relation between 24-h
urinary uric acid excretion and the risk of calcium oxalate
nephrolithiasis. In addition, the risk associated with different
levels of other urinary factors needs clarification. We
performed a cross-sectional study of 24-h urine excretion
and the risk of kidney stone formation in 3350 men and
women, of whom 2237 had a history of nephrolithiasis. After
adjusting for other urinary factors, urinary uric acid had a
significant inverse association with stone formation in men,
a marginal inverse association with risk in younger women,
and no association in older women. The risk of stone
formation in men and women significantly rose with
increasing urine calcium and oxalate, and significantly
decreased with increasing citrate and urine volume, with
the change in risk beginning below the traditional normal
thresholds. Other urinary factors were also associated with
risk, but this varied by age and gender. Our study does
not support the prevailing belief that higher urine uric
acid excretion increases the risk for calcium oxalate stone
formation. In addition, the current definitions of normal
levels for urinary factors need to be re-evaluated.
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The 24-h urine collection remains the cornerstone of
the evaluation of patients with nephrolithiasis.1 Higher levels
of urine calcium and oxalate appear to increase the risk
of calcium oxalate stone formation, while higher levels of
citrate and total volume may decrease the risk. However,
the magnitude of risk for different levels of each urinary
factor and whether the current ‘normal’ values are optimal
need clarification.
In addition, there remains substantial uncertainty about
the importance of urine uric acid. For over three decades,
some studies have suggested that urine uric acid, at least
in the hyperuricosuric range, is an important risk factor for
calcium oxalate stone formation,2,3 despite the lack of a clear
mechanism.4 Most of those studies were small, included
relatively few controls, and did not take into account other
urinary factors correlated with hyperuricosuria, such as urine
oxalate. The strongest evidence comes from a randomized
placebo-controlled trial of allopurinol in individuals with
calcium oxalate stone disease and isolated hyperuricosuria.5
The recurrence rate was reduced by more than half in
the allopurinol-treated group. However, as noted by the lead
investigator of that study in a subsequent review,6 it is
possible that the mechanism for reduction in the allopurinol
group may not be related to changes in urine uric acid.
We previously reported results from over 1000 men and
women with (n¼ 807) and without (n¼ 237) stone disease
who provided a single 24-h urine collection.7 In that study,
we found that risk of being a stone former decreased
significantly with increasing 24-h urine uric acid in men,
and there was no association in women. In order to examine
the independent association between urine uric acid and
stone formation and to quantify the magnitudes of asso-
ciations of other urine factors, we expanded our study
to include 3350 participants (2237 stone formers and 1113
controls) who performed 24-h urine collections. In addition,
2120 of these participants performed two 24-h urine
collections. Further, the large sample size permitted analyses
stratified by levels of different urinary factors (e.g., uric acid
stratified by urine pH).
RESULTS
Characteristics of the stone formers and controls are presen-
ted in Table 1. Compared with controls, the mean age of cases
who performed a 24-h collection was slightly lower in second
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Nurses’ Health Study cohort (NHS II) and Health Profes-
sionals Follow-up Study (HPFS). Mean body mass index
was higher in cases than controls in first Nurses’ Health
Study cohort (NHS I) and NHS II. Family history of stone
disease was substantially higher in NHS II and HPFS cases
(information was not available in NHS II).
Mean 24-h urine values from the first collection are
presented in Table 2. The multivariate adjusted results for
odds of being a stone former are presented in Table 3. The
results for individual urinary factors are discussed below.
Uric acid
In all three cohorts, mean urine uric acid did not significantly
differ between cases and controls (PX0.15) (Table 2). We
examined the correlations between urine uric acid and the
other urinary factors in all three cohorts. Among the cases,
the highest correlations were observed for creatinine (r¼
0.53–0.69; Po0.001), phosphate (r¼ 0.45–0.62; Po0.001),
and sodium (r¼ 0.42–0.47; Po0.001). The correlation bet-
ween uric acid and oxalate was higher in men (r¼ 0.42–0.50;
Po0.001) than in women (r¼ 0.30–0.40; Po0.001). The
correlation between uric acid and calcium in all three cohorts
was p0.40 (Po0.001).
When we assessed the prevalence of stone formers accord-
ing to categories of uric acid using the first collection, there
was no suggestion of an increased risk with increasing urine
uric acid (Table 3). In fact, in younger women there was a
marginally significant inverse association (P, trend¼ 0.06)
and in men a strong inverse association was seen (P, trend
o0.001). When both urine collections were considered, there
was a strong inverse association in both younger women and
men (P, trendo0.001). For example, compared with women
with mean 24-h urine uric acid excretion o400 mg day1,
the multivariate relative risk of being a stone former in those
with uric acid X800 mg day1 was 0.16 (0.04–0.60). The
multivariate relative risk for the similar comparison in men
was 0.10 (0.04–0.26). There was no significant association in
older women.
Because of the possibility that lower urine pH in some
of the cases could have caused precipitation of uric acid
crystals in the collection vials, and thus result in an under
measurement of the true 24-h uric acid excretion, we
analyzed the association between urine uric acid and risk of
being a stone former by pH categories (Table 4). In younger
and older women, there was no statistically significant
association for uric acid in any pH category. In men, a
significant inverse association was present in the two lowest
categories of urine pH; there was no evidence for a higher
risk in the two higher pH categories.
Based on information from a supplementary question-
naire sent to cases in all three cohorts, less than 1.5% of the
cases were taking allopurinol.
Table 1 | Characteristics of participants in the 24-h urine collection study by cohort and case status
NHS I NHS II HPFS
Variable Case (n=898) Control (n=403) Case (n=703) Control (n=296) Case (n=636) Control (n=414)
Age, year 66.1 (7.8) 65.4 (5.8) 47.5 (6.1)a 50.1 (5.2) 63.0 (9.3)a 64.6 (6.3)
Weight, kg 74.2 (15.6)a 70.4 (15.2) 75.0 (19.6) 73.1 (17.7) 83.4 (12.2) 84.0 (13.2)
Body mass index, kg m2 27.8 (5.7)a 26.1 (5.3) 27.8 (7.0)b 26.8 (6.3) 26.2 (3.4) 26.2 (3.4)
Family history, % NA NA 33%a 13.9% 21.5%a 13%
HPFS, Health Professionals Follow-up Study; NA, not available; NHS I, first Nurses’ Health Study cohort; NHS II, second Nurses’ Health Study cohort.
Values are means (s.d.) except where noted.
aPp0.01 for case compared with control within the cohort.
bPo0.05 for case compared with control within the cohort.
Table 2 | Mean (s.d.) 24-h urine values by cohort and case status
NHS I NHS II HPFS
Variable Case (n=898) Control (n=403) Case (n=703) Control (n=296) Case (n=636) Control (n=414)
Calcium, mg 202 (113)a 184 (95) 222 (101)a 190 (91) 218 (116)a 169 (91)
Oxalate, mg 30 (11)a 28 (10) 28 (11)a 26 (9) 41 (15)b 39 (13)
Uric acid, mg 452 (173) 450 (158) 525 (175) 514 (167) 621 (252) 641 (217)
Citrate, mg 614 (324)a 680 (307) 727 (322)c 785 (287) 684 (310)b 718 (306)
Potassium, mEq 59 (22)a 63 (21) 53 (21)a 59 (21) 75 (24)c 80 (26)
Sodium, mEq 143 (63) 138 (57) 154 (64) 153 (65) 187 (70)c 176 (71)
Magnesium, mg 99 (41)c 107 (38) 97 (36)b 103 (39) 125 (44) 123 (43)
Phosphate, mg 773 (262) 748 (246) 870 (297)b 828 (299) 1106 (340)a 1031 (307)
Creatinine, mg 1069 (260) 1042 (227) 1233 (298) 1209 (260) 1692 (395)c 1618 (391)
PH 5.9 (0.5)a 6.1 (0.5) 6.0 (0.5) 6.1 (0.5) 5.8 (0.5)b 5.9 (0.5)
Total volume, L 1.70 (0.65)a 2.00 (0.74) 1.58 (0.67)a 1.88 (0.77) 1.64 (0.62)a 1.81 (0.71)
HPFS, Health Professionals Follow-up Study; NHS I, first Nurses’ Health Study cohort; NHS II, second Nurses’ Health Study cohort.
aPp0.001 for case compared with control within the cohort.
bPo0.05 for case compared with control within the cohort.
cPp0.01 for case compared with control within the cohort.
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Table 3 | Multivariate relative risks for kidney stones
according to category of 24-h urinary excretion within
NHS I, NHS II, and HPFS
Cases Controls RR (CI)
NHS I
Calcium, mg
o100 152 73 1.00 (Ref.)
100–149 175 88 1.26 (0.84–1.91)
150–199 165 85 1.52 (0.99–2.34)
200–249 154 68 1.84 (1.17–2.90)
250–299 96 43 1.93 (1.15–3.24)
300–349 73 25 2.68 (1.46–4.93)
350+ 83 21 4.94 (2.53–9.67)
P, trend o0.001
Oxalate, mg
o20 100 63 1.00 (Ref.)
20–24 171 105 1.15 (0.75–1.77)
25–29 224 99 1.59 (1.03–2.46)
30–39 278 93 2.51 (1.59–3.96)
40+ 125 43 2.36 (1.35–4.13)
P, trend o0.001
Uric acid, mg
o400 353 161 1.00 (Ref.)
400–499 248 116 0.96 (0.69–1.33)
500–599 159 59 1.07 (0.70–1.64)
600–699 69 40 0.64 (0.37–1.09)
700–799 39 16 0.85 (0.40–1.82)
800+ 30 11 0.72 (0.29–1.80)
P, trend 0.30
Citrate, mg
o300 146 35 1.00 (Ref.)
300–399 91 30 0.72 (0.40–1.28)
400–499 110 46 0.63 (0.37–1.08)
500–599 121 61 0.50 (0.30–0.83)
600–699 106 48 0.56 (0.33–0.96)
700–799 105 47 0.54 (0.31–0.94)
800+ 219 136 0.33 (0.20–0.55)
P, trend o0.001
Magnesium, mg
o60 136 24 1.00 (Ref.)
60–69 67 32 0.35 (0.18–0.66)
70–79 97 39 0.39 (0.21–0.70)
80–99 215 108 0.33 (0.20–0.56)
100–119 150 76 0.32 (0.18–0.56)
120–139 108 53 0.31 (0.17–0.56)
140+ 125 71 0.22 (0.12–0.41)
P, trend o0.001
Potassium, mEq
o40 153 46 1.00 (Ref.)
40–49 185 61 0.97 (0.61–1.54)
50–59 167 87 0.70 (0.44–1.11)
60–69 153 73 0.85 (0.52–1.39)
70–79 88 56 0.78 (0.45–1.36)
80–89 71 35 1.08 (0.58–2.03)
90+ 81 45 0.95 (0.50–1.83)
P, trend 0.84
Sodium, mEq
o120 348 170 1.00 (Ref.)
120–139 141 59 1.30 (0.88–1.90)
140–159 119 46 1.30 (0.86–1.98)
160–179 89 35 1.36 (0.84–2.17)
180–199 66 38 0.92 (0.56–1.50)
200–219 38 22 0.90 (0.49–1.66)
Table 3 | Continued
Cases Controls RR (CI)
220+ 97 33 1.59 (0.94–2.70)
P, trend 0.07
Phosphate, mg
o600 227 114 1.00 (Ref.)
600–799 319 143 1.03 (0.74–1.44)
800–899 101 51 0.93 (0.58–1.48)
900–999 99 35 1.50 (0.88–2.57)
1000+ 152 60 1.00 (0.59–1.69)
P, trend 0.85
Total volume, l
o1.00 131 30 1.00 (Ref.)
1.00–1.24 119 32 0.76 (0.43–1.36)
1.25–1.49 134 39 0.64 (0.36–1.11)
1.50–1.74 130 55 0.45 (0.26–0.76)
1.75–1.99 121 57 0.37 (0.21–0.64)
2.00–2.24 93 59 0.28 (0.16–0.48)
2.25–2.49 53 36 0.25 (0.13–0.47)
2.50+ 117 95 0.22 (0.13–0.38)
P, trend o0.001
pH
o5.5 213 58 1.00 (Ref.)
5.5–5.9 272 125 0.69 (0.47–1.02)
6.0–6.4 258 131 0.83 (0.55–1.23)
6.5+ 155 89 0.88 (0.55–1.39)
P, trend 0.39
NHS II
Calcium, mg
o100 69 37 1.00 (Ref.)
100–149 92 72 0.89 (0.51–1.55)
150–199 162 75 1.58 (0.92–2.72)
200–249 131 45 2.73 (1.49–5.02)
250–299 102 32 3.28 (1.68–6.41)
300–349 65 19 3.60 (1.69–7.68)
350+ 82 16 5.86 (2.59–13.27)
P, trend o0.001
Oxalate, mg
o20 116 75 1.00 (Ref.)
20–24 167 70 1.78 (1.14–2.80)
25–29 158 64 1.81 (1.13–2.90)
30–39 173 65 2.09 (1.27–3.43)
40+ 89 22 3.58 (1.85–6.94)
P, trend o0.001
Uric acid, mg
o400 159 75 1.00 (Ref.)
400–499 190 76 1.01 (0.66–1.55)
500–599 151 61 0.91 (0.56–1.47)
600–699 105 42 0.69 (0.38–1.23)
700–799 47 23 0.51 (0.24–1.06)
800+ 51 19 0.44 (0.19–1.02)
P, trend 0.06
Citrate, mg
o300 49 8 1.00 (Ref.)
300–399 59 15 0.68 (0.25–1.81)
400–499 61 27 0.36 (0.15–0.91)
500–599 80 31 0.37 (0.15–0.90)
600–699 95 40 0.33 (0.14–0.81)
700–799 99 43 0.32 (0.13–0.76)
800+ 260 132 0.24 (0.11–0.56)
P, trend o0.001
Table 3 continued on following page
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Table 3 | Continued
Cases Controls RR (CI)
Magnesium, mg
o60 94 30 1.00 (Ref.)
60–69 44 33 0.36 (0.19–0.69)
70–79 83 27 0.82 (0.43–1.56)
80–99 178 61 0.77 (0.44–1.35)
100–119 130 61 0.48 (0.27–0.88)
120–139 95 37 0.51 (0.26–1.00)
140+ 79 47 0.35 (0.17–0.69)
P, trend 0.001
Potassium, mEq
o40 173 49 1.00 (Ref.)
40–49 175 57 1.00 (0.63–1.61)
50–59 138 64 0.80 (0.48–1.31)
60–69 91 50 0.69 (0.39–1.20)
70–79 62 32 0.82 (0.42–1.58)
80–89 29 20 0.59 (0.26–1.33)
90+ 35 24 0.78 (0.35–1.75)
P, trend 0.21
Sodium, mEq
o120 221 91 1.00 (Ref.)
120–139 87 46 0.68 (0.42–1.10)
140–159 102 46 0.96 (0.60–1.54)
160–179 90 28 1.15 (0.67–1.99)
180–199 49 24 0.83 (0.44–1.56)
200–219 55 19 0.87 (0.44–1.71)
220+ 99 42 0.85 (0.49–1.48)
P, trend 0.78
Phosphate, mg
o600 120 69 1.00 (Ref.)
600–799 201 80 1.73 (1.11–2.70)
800–899 104 47 1.47 (0.87–2.51)
900–999 80 31 1.75 (0.95–3.22)
1000+ 198 69 2.31 (1.26–4.25)
P, trend 0.08
Total volume, l
o1.00 138 38 1.00 (Ref.)
1.00–1.24 122 22 1.73 (0.93–3.21)
1.25–1.49 96 42 0.55 (0.31–0.96)
1.50–1.74 103 33 0.83 (0.54–1.51)
1.75–1.99 73 49 0.40 (0.22–0.70)
2.00–2.24 58 27 0.57 (0.29–1.10)
2.25–2.49 37 20 0.35 (0.17–0.75)
2.50+ 76 65 0.33 (0.18–0.61)
P, trend o0.001
pH
o5.5 104 31 1.00 (Ref.)
5.5–5.9 251 105 0.81 (0.49–1.33)
6.0–6.4 238 104 1.05 (0.63–1.76)
6.5+ 110 56 1.20 (0.66–2.19)
P, trend 0.19
HPFS
Calcium, mg
o100 91 86 1.00 (Ref.)
100–149 92 115 0.97 (0.63–1.50)
150–199 134 78 2.14 (1.36–3.34)
200–249 110 63 2.17 (1.34–3.51)
250–299 78 35 3.29 (1.86–5.83)
300–349 54 20 3.80 (1.94–7.41)
350+ 77 17 6.23 (3.02–12.86)
P, trend o0.001
Table 3 | Continued
Cases Controls RR (CI)
Oxalate, mg
o25 36 51 1.00 (Ref.)
25–29 72 45 2.35 (1.28–4.32)
30–39 203 146 1.90 (1.12–3.22)
40–49 178 92 2.67 (1.52–4.70)
50+ 147 80 3.22 (1.72–6.05)
P, trend 0.005
Uric acid, mg
o400 116 46 1.00 (Ref.)
400–499 79 67 0.48 (0.29–0.80)
500–599 115 79 0.49 (0.30–0.80)
600–699 112 76 0.41 (0.24–0.68)
700–799 82 48 0.38 (0.21–0.68)
800+ 132 98 0.22 (0.12–0.40)
P, trend o0.001
Citrate, mg
o300 58 26 1.00 (Ref.)
300–399 60 37 0.59 (0.31–1.15)
400–499 57 43 0.49 (0.25–0.94)
500–599 101 47 0.59 (0.32–1.10)
600–699 82 59 0.42 (0.23–0.78)
700–799 70 53 0.35 (0.18–0.68)
800+ 208 149 0.30 (0.17–0.56)
P, trend o0.001
Magnesium, mg
o60 24 13 1.00 (Ref.)
60–69 27 21 0.72 (0.28–1.85)
70–79 35 30 0.63 (0.26–1.55)
80–99 97 61 0.78 (0.35-1.78)
100–119 125 94 0.60 (0.27–1.35)
120–139 119 67 0.83 (0.37–1.89)
140+ 209 128 0.63 (0.28–1.44)
P, trend 0.53
Potassium, mEq
o40 22 13 1.00 (Ref.)
40–49 70 29 1.38 (0.57–3.30)
50–59 89 59 0.87 (0.38–2.01)
60–69 108 64 1.05 (0.46–2.42)
70–79 98 72 0.84 (0.36–1.97)
80–89 87 42 1.31 (0.54–3.18)
90+ 162 135 0.77 (0.32–1.86)
P, trend 0.13
Sodium, mEq
o120 98 75 1.00 (Ref.)
120–139 69 52 1.07 (0.65–1.76)
140–159 74 66 0.92 (0.57–1.48)
160–179 79 58 0.98 (0.60–1.62)
180–199 69 40 1.27 (0.73–2.19)
200–219 64 32 1.45 (0.82–2.58)
220+ 183 91 1.47 (0.89–2.42)
P, trend 0.14
Phosphate, mg
o600 20 22 1.00 (Ref.)
600–799 94 77 1.40 (0.69–2.87)
800–899 54 50 1.31 (0.60–2.84)
900–999 90 56 1.64 (0.77–3.49)
1000+ 378 209 1.85 (0.88–3.91)
P, trend 0.12
Table 3 continued on following page
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Calcium, oxalate, and citrate
In all three cohorts, urine calcium and oxalate were signi-
ficantly higher in cases compared with controls and urine
citrate was lower (Table 2). Using logistic regression, we
found that the risk of stone formation increased with increa-
sing urine calcium (P, trend o0.001) and oxalate (P, trend
p0.005), and decreased with increasing citrate (P, trend
o0.001) (Table 3). Importantly, the risk began to change
significantly even within the ‘normal’ range. For example,
compared with men with urine calcium excretion
o100 mg day1, the relative risk of being a stone former
for men with calcium excretion 150–199 mg day1 was 2.14
(1.36–3.34). Similar results were seen when the two urine
samples were analyzed.
The frequency of use of a thiazide diuretic, which could
reduce urine calcium excretion, reported in the questionnaire
before the urine collection was 8.6% in HPFS, 13.3% in NHS
I, and 6.6% in NHS II. After excluding those individuals who
reported thiazide use before the urine collection, the results
were materially unchanged.
Other urine factors
In all three cohorts, mean urine potassium and mean total
volume were significantly lower in cases (Table 2). Urine
sodium was higher in male cases and urine phosphate was
higher in male and younger female cases. Magnesium was
lower in female but not male cases.
Table 3 | Continued
Cases Controls RR (CI)
Total volume, l
o1.00 81 41 1.00 (Ref.)
1.00–1.24 113 49 1.02 (0.60–1.74)
1.25–1.49 115 68 0.60 (0.35–1.01)
1.50–1.74 84 60 0.46 (0.26–0.81)
1.75–1.99 94 44 0.73 (0.41–1.31)
2.00–2.24 57 54 0.36 (0.20–0.66)
2.25–2.49 33 29 0.34 (0.16–0.70)
2.50+ 59 69 0.26 (0.14–0.49)
P, trend o0.001
pH
o5.5 159 101 1.00 (Ref.)
5.5–5.9 251 138 1.65 (1.14–2.40)
6.0–6.4 173 123 1.72 (1.15–2.58)
6.5+ 53 52 1.74 (1.00–3.02)
P, trend 0.03
CI, confidence interval; HPFS, Health Professionals Follow-up Study; NHS I, first Nurses’
Health Study cohort; NHS II, second Nurses’ Health Study cohort; RR, relative risk.
RRs are adjusted for age, urinary creatinine, and all other urinary factors. Case and
control numbers refer to the single 24-h urine collection.
Table 4 | Multivariate relative risks (95% CI) for kidney stones according to category of 24-h urine uric acid excretion and urine
pH within NHS I, NHS II and HPFS
24-h urine pH categories
NHS I o5.5 5.5–5.9 6.0–6.4 46.5
Cases/controls 213/58 272/125 258/131 155/89
Uric acid, mg
o400 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
400–499 1.49 (0.65–3.45) 0.85 (0.48–1.53) 1.14 (0.60–2.20) 0.81 (0.39–1.71)
500–599 1.94 (0.57–6.59) 1.22 (0.57–2.61) 0.67 (0.30–1.49) 1.35 (0.52–3.50)
600–699 0.62 (0.16–2.48) 0.60 (0.22–1.66) 0.46 (0.18–1.17) 1.68 (0.34–8.36)
700–799 2.28 (0.18–28.62) 1.85 (0.38–8.97) 0.59 (0.16–2.12) 0.38 (0.06–2.62)
800+ 1.10 (0.06–20.35) 0.88 (0.19–4.20) 0.94 (0.20–4.48) 0.14 (0.01–2.61)
P, trend 0.89 1.00 0.25 0.88
NHS II
Cases/controls 104/31 251/105 238/104 110/56
Uric acid, mg
o400 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
400–499 0.56 (0.17–1.80) 0.86 (0.39–1.92) 1.42 (0.65–3.08) 1.22 (0.41–3.62)
500–599 0.36 (0.08–1.53) 1.19 (0.50–2.84) 1.45 (0.61–3.45) 0.46 (0.14–1.55)
600–699 1.04 (0.09–12.24) 0.79 (0.28–2.26) 0.94 (0.36–2.42) 0.63 (0.10–3.94)
700–799 0.42 (0.06–3.08) 0.94 (0.26–3.45) 0.48 (0.12–1.97) 0.34 (0.03–3.68)
800+ 0.13 (0.01–2.46) 0.68 (0.16–2.88) 1.06 (0.25–4.43) 0.06 (0.004–0.94)
P, trend 0.42 0.97 0.76 0.06
HPFS
Cases/controls 159/101 251/138 173/123 53/52
Uric acid, mg
o400 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
400–499 0.48 (0.19–1.22) 0.33 (0.11–1.05) 0.34 (0.11–1.05) 0.28 0.04–1.95)
500–599 0.41 (0.17–0.94) 0.22 (0.07–0.68) 0.62 (0.21–1.85) 0.57 (0.08–4.29)
600–699 0.49 (0.17–1.46) 0.15 (0.05–0.47) 0.42 (0.14–1.32) 0.89 (0.11–7.37)
700–799 0.78 (0.22–2.77) 0.19 (0.05–0.67) 0.24 (0.07–0.86) 0.64 (0.08–5.39)
800+ 0.28 (0.08–0.91) 0.08 (0.02–0.29) 0.20 (0.05–0.81) 0.78 (0.05–11.43)
P, trend 0.02 o0.001 0.11 0.38
CI, confidence interval; HPFS, Health Professionals Follow-up Study; NHS I, first Nurses’ Health Study cohort; NHS II, second Nurses’ Health Study cohort.
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The risk of stone formation decreased with increasing
urine volume (P, trendo0.001) in all three cohorts (Table 3).
For other urine factors, significant associations varied by
cohort. Magnesium was strongly inversely associated with
risk in women (P, trend p0.001) but not in men. Sodium
was marginally associated with an increased risk in older
women (P, trend¼ 0.07). Phosphate was marginally asso-
ciated with an increased risk in younger women (P, trend¼
0.08). Only in men was increasing urine pH associated with
increasing risk (P, trend¼ 0.03). When both urine collections
were considered, the associations for these last three factors
became more strongly associated with risk. In addition,
sodium (P, trend o0.001) and phosphate (P, trend¼ 0.04)
became significantly associated with increased risk in men,
and pH was associated with increased risk in younger women
(P, trend¼ 0.03).
DISCUSSION
The findings from this study involving over 3300 stone
formers and controls strongly suggest that higher urine
uric acid is not associated with a higher risk of being a
stone former. In fact, in younger women and men there was
a strong inverse association with uric acid. This study also
quantified the magnitudes of the independent associations
for the commonly measured urine factors. As expected,
higher risks were observed with increasing urine calcium and
oxalate and lower risks with increasing citrate and total
volume. Although clinically several of these factors tend to be
considered in terms of being high (e.g., hypercalciuria) or
low (e.g., hypocitraturia), our results suggest there are no
discrete risk groups, rather risk varies across a wide range of
values. Further, associations for some urine components vary
by age and sex.
Our results challenge the prevailing belief that uric acid
increases the risk of calcium oxalate stone formation, the
most common type of kidney stone.8 Why has uric acid been
generally accepted to be a risk factor for stone formation?
Some case series and observational studies reported that
patients with higher uric acid were more likely to have stone
recurrence.2,9 The most compelling evidence comes from a
randomized placebo-controlled trial published in 1986.5 This
3-year study of 60 individuals with calcium oxalate stone
disease, normal urine calcium, and elevated uric acid found a
50% reduction in stone growth or new stone formation in the
participants assigned to allopurinol, who had a 40%
reduction in urine uric acid.
However, not all previous studies found differences in
urine uric acid excretion between cases and controls.9,10 In
addition, Ettinger, the lead investigator of the randomized
allopurinol trial,5 critically reviewed the literature6 and
concluded that ‘epidemiologic and laboratory studies provide
only equivocal support for a synergistic relationship’ between
uric acid and calcium oxalate stone formation. Grover and
Ryall4 reviewed the laboratory literature and found little
scientific support for the two most commonly proposed
mechanisms by which uric acid would increase the likelihood
of calcium oxalate stone formation: epitaxy and reduction
in the inhibitory activity of urinary glycosaminoglycans. The
apparent protective action of allopurinol may be related to
actions beyond inhibition of xanthine oxidase; allopurinol
has been shown to have a variety of effects beyond lowering
uric acid production, including improvement of endothelial
dysfunction and reducing oxidative stress,11–14 which may
reduce stone formation via a mechanism that does not
involve a change in urine uric acid. Clearly, more work needs
to be performed to determine what, if any, role uric acid plays
in calcium oxalate stone formation, keeping in mind the
possibility that higher levels may actually reduce the risk.
Urine factors other than uric acid clearly play an impor-
tant role in stone formation. While we and others have
described the importance of calcium, oxalate, citrate, and
total volume, this study adds important new information.
It is now clear that the generally accepted definitions of
‘normal’ are not appropriate. The dichotomization of indi-
vidual urine values into either ‘normal’ or ‘abnormal’ ignores
the undoubtedly continuum of risk based on the urinary
composition for several of the urine factors. The risk of stone
formation begins to rise at levels of urine calcium and oxalate
and decreases at levels of urine citrate, that traditionally
would be considered in the normal range (Table 3).
Urine sodium, magnesium, phosphorus, and pH have
received less attention, but this study suggests these are
important risk factors as well. In men and older women,
higher urine sodium (a direct reflection of dietary sodium
intake) was associated with a higher risk of being a stone
former. Higher sodium intake has been suggested to increase
risk by raising urine calcium excretion,15 but in our study the
association was independent of the urinary calcium level. It is
unclear why no association was seen for sodium in younger
women. Magnesium has been proposed to lower the risk of
stone formation by reducing oxalate absorption16 or by
forming soluble complexes with oxalate in the urine. Higher
urine magnesium reduced the risk of being a stone former in
women but not in men; this was independent of urinary
oxalate, supporting a role as a urinary inhibitor. Although
urine phosphate is a risk factor for calcium phosphate stones,
its role in calcium oxalate stone formation is uncertain.
We found that higher urinary phosphate independently
increased the risk of kidney stones in men and younger but
not older women. Whether these findings relate to an
unknown mechanism for calcium oxalate stone formation
or only to calcium phosphate stones requires further study.
Finally, the urine pH findings deserve comment. Uric acid
stones form only at low urine pH and pure calcium
phosphate stones only at higher pH. In men with two urine
collections, we observed a consistent increase in kidney stone
risk with increasing urine pH. As with urine phosphate, it is
uncertain if this finding relates only to calcium phosphate
stone formation, but the increase in risk starts in the urine
pH range of 5.5 to 5.9, levels at which calcium phosphate
stones would not form, and thus raises the possibility that
this may be important for calcium oxalate stones.
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There are several limitations of this study. This study did
not include younger men or very young women. Because the
participants were predominantly Caucasian, the results may
not be generalizable to other racial groups. The 24-h urine
gives a picture of the average excretion over the day, but
does not provide information about periods of high and low
concentration. The postprandial increase in concentration of
urinary factors may be more important for crystal formation
than the 24-h excretion.17 Errors in the collection procedure
are known to occur, but we excluded results from individuals
who had implausibly low 24-h creatinine values. There may
also be errors in the measurement of urine uric acid either
due to factors in the urine or in the assay. The cases
performed the collections after their stone event; however,
the associations with most of the urine factors (e.g., calcium,
oxalate, citrate, volume) were in the expected direction,
suggesting little if any differences from the urine composition
before stone diagnosis. The vast majority of the cases were
not taking medication (e.g., thiazide, allopurinol) that could
affect urine composition and prevent stone recurrence.
Finally, we do not have information about stone composition
for all participants. However, given the demographics of the
participants, the independent association with urinary
oxalate, and our own unpublished data from review of stone
composition reports in medical records, more than 80% are
likely to have predominantly calcium oxalate stones.8
The results from this study may influence clinical practice
as well as future scientific studies. First, the current defini-
tions of ‘normal’ for many of the urinary factors (e.g.,
calcium, oxalate, citrate) need to be re-evaluated. The risk
of stone formation undoubtedly begins to increase well
before the traditionally accepted definitions. For example, an
elevation in risk was evident starting with the urine calcium
excretion of 150–199 mg day1. Second, there is insufficient
justification for using different cutpoints for men and women
with respect to stone formation, at least for calcium, oxalate
and citrate. Third, stone formation is a complex disorder, and
the individual and independent contribution of multiple
factors needs to be appreciated. This underscores the impor-
tance of studies that examine actual stone formation rather
than just changes in urine composition. Finally, our data do
not support the prevailing belief that higher urine uric acid is
a risk factor for calcium oxalate stone formation. While
current recommendations to reduce urine uric acid may be
beneficial for reducing the risk of recurrent stone formation
(e.g., reducing purine intake, prescribing allopurinol), the
mechanisms for these interventions may be independent of
their uric acid-lowering effect.
MATERIALS AND METHODS
Nurses’ Health Study I. The NHS I was established in 1976 when
121 700 female registered nurses aged 30–55 years and residing in
one of 11 states completed and returned the baseline questionnaire.
Nurses’ Health Study II. The NHS II was established in 1989
when a younger cohort of 116 671 female nurses aged 25–42 years
and residing in one of 15 states returned the baseline questionnaire.
Health Professionals Follow-up Study. In 1986, 51 529 male health
professionals aged 40–75 years from all 50 states returned the
baseline questionnaire and constitute the HPFS cohort.
All three cohorts have been followed by biennial mailed
questionnaires, which ask about lifestyle practices and other expo-
sures of interest, as well as newly diagnosed diseases. The follow-up
for all three cohorts exceeds 90%.
Ascertainment of kidney stones
The biennial questionnaires have asked whether a participant had
been diagnosed with a kidney since 1986 in HPFS, 1991 in NHS II,
and 1992 in NHS I. We mailed a supplementary questionnaire
to those reporting a first diagnosis of nephrolithiasis to obtain
additional information, including symptoms and stone type. Since
2002, we have been requesting permission to obtain medical records
related to the diagnosis of nephrolithiasis from newly diagnosed
cases in all three cohorts. Review of medical records has confirmed
the diagnosis of stone disease in over 90% of the cases.
Urine collections
Twenty-four-hour urine samples from participants with a history
of kidney stones confirmed by review of the supplementary
questionnaire and from randomly selected controls were collected
in two cycles. In the first cycle, which spanned from 1994 to 1999,
we obtained one 24-h urine collection from 807 stone formers
and 239 controls.7 The second cycle began in 2003 when we invited
additional stone formers and randomly selected controls to
perform two 24-h urine collections. In the first cycle, participants
were ineligible if they were 470 years of age in HPFS or 465 years
in NHS I, or had a history of cancer or cardiovascular disease.
In the second cycle, participants were ineligible if they were
older than 75 years of age or had a history of cancer (other than
non-melanoma skin cancer). Those with a history of stones
performed the collections after they had been diagnosed with
nephrolithiasis.
The 24-h urine collections were performed using the system
provided by Mission Pharmacal (San Antonio, TX, USA). We sent
a kit containing all the necessary supplies to participants agreeing
to collect a 24-h specimen. The 4-l jug contained a marker-
impregnated sponge attached to the bottom as well as preservative
to prevent bacterial growth. To assist in urine collection, female
participants were sent specially designed ‘hats’ and male participants
were sent urinals. Upon completion of the collection, participants
poured samples into two small vials, one of which contained acid
preservative. The vials were returned to Mission Pharmacal in
a prepaid self-addressed FedEx mailer. The concentration of the
marker was used to calculate the total volume of the collection.
Analytic procedures used for the urine measurements. Calcium
and magnesium were measured by an atomic absorption spectro-
photometer. Creatinine, uric acid, citrate, and phosphorus were
measured by a Cobas centrifugal analyzer. Oxalate was analyzed by ion
chromatography. Sodium and potassium were determined directly by
flame emission photometry. A pH electrode measured the urine pH.
We previously sent blinded split samples to assess reproducibility;
the coefficients of variation for all factors analyzed were less than 10%.
Among the eligible cases, 77% of HPFS men, 53% of NHS I, and
55% of NHS II women agreed to perform at least one collection. Of
those who agreed to participate, the completion rates were 77% in
HPFS, 84% in NHS I, and 68% in NHS II.
From the randomly selected HPFS controls, 52% agreed to
participate and 76% of those completed at least one collection. The
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participation and completion rates in controls were 48 and 86% for
NHS I and 49 and 48% for NHS II.
When examined by case status, there were no substantial
differences in HPFS between participants who collected urine and
those who did not and only minor differences in the female cohorts.
The largest difference was that the controls who provided a sample
had a mean body mass index that was lower by 2.2 kg m2 in NHS I
and 1.6 kg m2 in NHS II. There were no important differences in
intake of dietary calcium, sodium, and animal protein. In this study,
after exclusions 1301 NHS I participants, 999 NHS II participants,
and 1050 HPFS participants provided at least one 24-h urine
collection. In the three cohorts, 2120 participants completed two
collections.
Statistical analysis
In the primary analysis, we included participants who provided a
single 24-h urine collection. If a participant submitted more than
one urine collection, we used the first sample. To exclude those with
incomplete collections, we limited the analysis to participants whose
24-h urine creatinine values were greater than 600 mg for women
and 800 mg for men. Based on this criterion,p3% of the female and
o2% of the male urines were excluded. In secondary analyses, we
included only those participants who submitted two 24-h urine
collections. For these analyses, participants were included if the
creatinine value in each urine collection differed by less than 30%
from the mean creatinine value of the two collections and the
individual collections met the minimum creatinine values stated
above. Values for each urinary factor were obtained by calculating
the arithmetic mean of the two collections.
Data from stone formers and non-stone formers in each cohort
were analyzed separately. Categorical variables were compared using
the w2-test, and continuous variables were compared with the t-test.
Logistic regression was used to calculate relative risks of being a
stone former after adjusting simultaneously for age and all of the
24-h urinary factors. Categories for the urinary factors were selected
based on clinically reasonable increments.
Data were analyzed by using SAS software, version 9.1 (SAS
Institute Inc., Cary, NC, USA). All P-values are two-tailed. The
research protocol for this study was reviewed and approved by the
institutional review board of Brigham and Women’s Hospital.
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